NPPB and hydrops fetalis: In the PARALLAX (Prospective Comparison of ARN Inhibition vs Comorbidity-Associated Conventional Therapy on Quality of Life and Exercise Capacity) trial, in patients with HF with an LVEF of >40%, sacubitril-valsartan resulted in a greater reduction in NT-proBNP levels than for those in the comparator group (Table 2).68